Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TAK-928

Other · developed by TAKEDA PHARMACEUTICAL CO

Phase 3 Most advanced trial
TAK Developer
1 Registered trials

What is TAK-928?

TAK-928 is an agent administered by intravenous infusion. It is being studied in immuno-oncology (IO)-resistant squamous and nonsquamous non-small cell lung cancer (NSCLC).

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Oncology
Developer
TAKEDA PHARMACEUTICAL CO (TAK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07217301 Phase 3 IO Resistant Squamous and Nonsquamous NSCLC Recruiting TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

IO Resistant Squamous and Nonsquamous NSCLC

More from TAKEDA PHARMACEUTICAL CO

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the TAK page.

Follow TAK, the company behind TAK-928

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.